Clinical Trials
52 trialsEvaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
UNC Lineberger Comprehensive Cancer Center
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
St. Jude Children's Research Hospital
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
UNC Lineberger Comprehensive Cancer Center
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
HESTIA
Baylor College of Medicine
CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms
The General Hospital of Western Theater Command
CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
Affiliated Hospital to Academy of Military Medical Sciences
GRAIN
Baylor College of Medicine
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
UNC Lineberger Comprehensive Cancer Center
Epigenetic Reprogramming in Relapse/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
CD123 Redirected T Cells for AML in Pediatric Subjects
University of Pennsylvania
Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL
Chinese PLA General Hospital
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
University of Maryland, Baltimore
Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL
Chinese PLA General Hospital
Axi-cel in CNS Lymphoma
Dana-Farber Cancer Institute
Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL
Chinese PLA General Hospital
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
University Health Network, Toronto
Lentivirally Redirected CD123 Autologous T Cells in AML
University of Pennsylvania
BMT-13
University of Illinois at Chicago
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences
Immunotherapy for the Treatment of Advanced Solid Tumor
Tongji Hospital
Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML
First Affiliated Hospital Xi'an Jiaotong University
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
M.D. Anderson Cancer Center
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
COBALT
University College, London
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow University
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
Second Affiliated Hospital, School of Medicine, Zhejiang University
RRTCLAlloSCT
Keimyung University Dongsan Medical Center
A Phase I Trial of Anti-GD2 T-cells (1RG-CART)
Cancer Research UK
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Therapeutic Advances in Childhood Leukemia Consortium
FLAGINEXOR
PETHEMA Foundation
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma
Lymphoma Study Association
MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
Zhejiang University
NY-ESO-1 TCR (TAEST16001)for Patients With Advanced NSCLC
Guangzhou Institute of Respiratory Disease
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
University of Illinois at Chicago
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
M.D. Anderson Cancer Center
Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma
Peking University
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL
Massachusetts General Hospital
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
University of Chicago
Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Chinese PLA General Hospital
ZOLINZA
Samsung Medical Center
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
University of Michigan Rogel Cancer Center
AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy
Changhai Hospital
Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant
University of Arkansas
Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)
WiSP Wissenschaftlicher Service Pharma GmbH